IL3RA and CD4+/CD56+ hematodermic neoplasm: The CADENZA clinical trial (NCT 03386513) is enrolling two expansion cohorts for adult patients with CD123-positive BPDCN: one cohort is enrolling patients with frontline/untreated BPDCN disease; the other cohort is enrolling patients with relapsed/refractory BPDCN which may have had up to three lines of prior therapy, including CD123 targeting and stem cell transplantation [77].